Cancer Letters

Cancer Letters

Volume 408, 1 November 2017, Pages 164-173
Cancer Letters

Original Article
Discovery of peptide drug carrier candidates for targeted multi-drug delivery into prostate cancer cells

https://doi.org/10.1016/j.canlet.2017.08.040Get rights and content

Highlights

  • Criteria are used to isolate cell targeting peptides from phage display libraries.

  • Peptides were internalized by different prostate cancer cells.

  • One selected peptide was used to prepare multi-drug peptide-drug-conjugates.

  • Multi-drug peptide-drug-conjugates can produce novel synergistic cytotoxicities.

Abstract

Metastatic castration-resistant prostate cancer (mCRPC) remains essentially incurable. Targeted Drug Delivery (TDD) systems may overcome the limitations of current mCRPC therapies. We describe the use of strict criteria to isolate novel prostate cancer cell targeting peptides that specifically deliver drugs into target cells. Phage from a libraries displaying 7mer peptides were exposed to PC-3 cells and only internalized phage were recovered. The ability of these phage to internalize into other prostate cancer cells (LNCaP, DU-145) was validated. The displayed peptides of selected phage clones were synthesized and their specificity for target cells was validated in vitro and in vivo. One peptide (P12) which specifically targeted PC-3 tumors in vivo was incorporated into mono-drug (Chlorambucil, Combretastatin or Camptothecin) and dual-drug (Chlorambucil/Combretastatin or Chlorambucil/Camptothecin) PDCs and the cytotoxic efficacy of these conjugates for target cells was tested. Conjugation of P12 into dual-drug PDCs allowed discovery of new drug combinations with synergistic effects. The use of strict selection criteria can lead to discovery of novel peptides for use as drug carriers for TDD. PDCs represent an effective alternative to current modes of free drug chemotherapy for prostate cancer.

Introduction

Metastatic castration-resistant prostate cancer (mCRPC) is essentially incurable [1] and in 2014 the disease accounted for approximately 30,000 deaths in the US alone [2]. Androgen deprivation therapy, for many years the standard first-line treatment for mCRPC is initially effective in most patients, but disease inevitably progresses [3]. Newer molecular targeted therapies have shown clinical benefit for patients with mCRPC including chemotherapies, immunotherapies and radiopharmaceuticals. However it is not yet clear how to sequence these therapies in individual patients to achieve long-term clinical efficacy with low toxicity, nor is it clearly understood how cross-resistance to each component develops (reviewed in Ref. [3]. The continual genetic evolution of prostate cancer (PrC) cells is an additional complication [4], requiring repeated patient monitoring to update chemotherapy regimens [3], a process of “cat-and-mouse” that is expensive and carries implications for drug toxicity, patient morbidity and survival.

Targeted Drug Delivery (TDD) systems based for example on antibodies [5] and peptides [6]may overcome many of the limitations of current mCRPC therapies. For example our own studies demonstrate that attachment of a small ligand- or peptide-cancer cell targeting agent to cytotoxic drugs affords several advantages that include: specific delivery of drug to the target cell, regulated cytotoxicity, bypassing of drug resistance, reversal of drug resistance, delivery of higher drug payloads and simultaneous delivery of cytotoxic drugs with different mechanisms of action [7], [8], [9], [10], [11], [12].

TDDs assume the presence of an appropriate cell surface target molecule and one of the most studied mCRPC related cell surface components is Prostate Specific Membrane Antigen (PSMA), a 100 KDa type II transmembrane glycosylated protein. PSMA is very commonly expressed on PrC cells. The biology and clinical relevance of PMSA expression has been extensively researched and it has been targeted by a diverse selection of small ligands, antibodies and peptides to which have been conjugated a variety of radiolabels and drugs [13], [14]. Some of these constructs have been evaluated clinically (some are still ongoing, see www.clinicaltrials.gov) and FDA-approved PSMA-targeted products are available for diagnostic imaging [15]. Despite these advances, many questions remain about the efficacy of PSMA-targeted therapeutics [13], [14], [15].

The most clinically advanced peptide-based TDD systems are bioconjugates incorporating analogues of the natural hormone Gonadotropin-Releasing Hormone (GnRH) (reviewed in Ref. [16]) that target the GnRH receptor. However, this approach has several limitations. a) GnRH receptors are also present on a variety of normal tissues. b) Due to the structure of the receptors, internalization of the bioconjugate is relatively slow; c) It has proven very difficult to prepare active conjugates of these analogues with drugs other that anthracyclines such as doxorubicin [16].

To expand the spectrum of targeting peptides for TDD, phage display technology is being used [17], [18]. Jayanna et al. [19] and also Fagbohun et al. [20] used phage display to isolate clones that were internalized by PrC cells, with the aim of using the phage themselves, not the isolated peptides, as delivery vehicles. The Arap group [21]recently described phage clones internalized by prostate cancer cells in bone metastases, however activity with isolated peptides was not described. Other studies focused on using phage libraries to isolate peptides binding other known receptors on PrC cells [22], [23], [24], [25]. However, the peptides were mainly designed to inhibit the activity of a receptor.

Our goal was different. We set out to use phage display peptide libraries to isolate novel PrC targeting peptides for use in Peptide-Drug-Conjugates (PDCs) that would be effective in the treatment of mCRPC. Our approach was to use unbiased exposure of the phage library to mCRPC cells, without selecting for peptides that bound a pre-defined receptor. We used strict criteria to select appropriate phage clones and their displayed peptides: a) internalization of the phage into the target cell, b) target cell specificity c) uptake of the synthesized display peptide into target cells d) accumulation of the peptide into tumor and e) incorporation of the peptide into both mono-drug and dual-drug-PDCs that killed PrC cells.

We compared a commercial phage library expressing 7-mer linear peptides with the same library after it had been injected into a normal mouse. Phage clones recovered from the bloodstream of the mouse were assumed not to have effective affinity for normal tissues and were not degraded by the liver. This manipulation significantly reduced the number of clones in the library, thus increasing the probability of “fishing out” appropriate on-target clones. Indeed the two peptides (P10 and P12) that we have so far tested most thoroughly and are reporting on here were both derived from the second library. These peptides are active on a range of metastatic prostate cancer cell lines but not on normal cells. Importantly, the preparation of active peptide-dye conjugates was found to be terminus dependent and this guided the synthesis of PDCs that were cytotoxic to PrC target cells. These peptides are now moving into an advanced program of pre-clinical testing as a potential novel targeted drug therapy for mCRPC.

Section snippets

Cells and reagents

The cell lines used in this study represented malignant prostate cancer (PC-3, LNCaP, DU-145), cervical cancer (HeLa) and human embryonic kidney cells (HEK-293). All cells were obtained from the ATCC. PC-3, DU-145 and LNCaP were grown in RPMI 1640 (Thermo Fischer Scientific, Waltham, Ma., USA). HeLa were grown in MEM Alpha medium and HEK-293 in DMEM (Thermo Fischer). All media were supplemented with 10% FBS (Thermo Fischer), 3 mM l-Glutamine and antibiotics (Biological Industries, Bet Haemek,

PC-3 cells internalize phage

Both the parent Ph.D-7 phage library (L1) and the in vivo absorbed (L2) phage library were exposed to PC-3 and internalized phage were retrieved. After titration, phage from 15 individual plaques were recovered. Sequencing of the peptide inserts showed that only one peptide sequence was obtained from each plaque, indicating the clonality of the phage in each plaque. Of the plaques isolated from the original (L1) library (Table 1), 2 displayed the same sequence, another two displayed a different

Discussion

Our study describes new approaches to utilizing phage display peptide libraries for developing Targeted Drug Delivery systems for prostate cancer therapy. First, instead of targeting classical prostate cancer surface markers such as PSMA [23], or GnRH receptors [16] we used a screening strategy that favors the discovery of novel peptides that target potentially other cell surface components that would serve as appropriate ports of drug delivery into the cell. Second, for biological (lack of

Funding sources

Ariel University Research Authority Grant # RA1500662.

Ariel R&D Tech Transfer Grant #AC1500061.

OB and BR were supported by graduate student stipends from Ariel University.

Acknowledgements

The authors wish to thank Lena Tuchinsky for her expert assistance with the confocal microscopy and the animal studies. The research was funded by the Ariel University Research Authority and the Ariel University Technology Transfer Office (Ariel R&D Ltd).

References (34)

  • W. Wang et al.

    Screening a phage display library for a novel FGF8b-binding peptide with anti-tumor effect on prostate cancer

    Exp. Cell Res.

    (2013)
  • R. Siegel et al.

    Cancer statistics

    CA Cancer J. Clin.

    (2014)
  • T. Mitchell et al.

    The genomic evolution of human prostate cancer

    Br. J. Cancer

    (2015)
  • A. Parslow et al.

    Antibody–drug conjugates for cancer therapy

    Biomedicines

    (2016)
  • M.A. Firer et al.

    Specific destruction of hybridoma cells by antigen-toxin conjugates demonstrate an efficient strategy for targeted drug therapy in leukemias of the B cell lineage

    Leuk. Lymphoma

    (2003)
  • G. Gellerman et al.

    Drug resistance to chlorambucil in murine B-cell leukemic cells is overcome by its conjugation to a targeting peptide

    Anticancer. Drugs

    (2013)
  • Y. Gilad et al.

    Dual-drug RGD conjugates provide enhanced cytotoxicity to melanoma and non-small lung cancer cells

    Biopolymers

    (2015)
  • Cited by (0)

    View full text